News Sentiment

TCRX sentiment intelligence

Tscan Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.91 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-16.1% over one week, -0.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -16.1% Price reacting lower
Trend fit Trend inactive -0.6% over four weeks
Fair value -72.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 25
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 7
Stock Titan 5
GlobeNewswire 3
Moomoo 3
Quartr 2
Investing.com 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 17
Analyst action 9
Guidance 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
MSN Direct company coverage

TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates

TScan Therapeutics, Inc. (TCRX) announced a Q1 loss, missing revenue estimates. This indicates a challenging start to the fiscal year for the company, with financial performance not meeting analyst expectations.

Tone
Negative 29/100
Event
Earnings
Published
17 Jul 2026 17:39
Source
MSN
Quartr Direct company coverage

TScan Therapeutics (TCRX) Q4 2025 earnings summary

TScan Therapeutics (TCRX) reported its Q4 2025 earnings, highlighting positive updated data from the ALLOHA Phase 1 heme trial and significant progress in its clinical pipeline, including FDA clearance for new INDs and the launch of a pivotal trial for TSC-101. Financially, the c

Tone
Positive 70/100
Event
Earnings
Published
10 Jul 2026 12:10
Source
Quartr
Quartr Direct company coverage

TScan Therapeutics (TCRX) Status Update Summary

TScan Therapeutics (TCRX) provided a status update on its hematologic malignancy program, highlighting positive results from the Phase 1 ALLOHA trial for TSC100 and TSC101, which showed significant relapse reduction and improved event-free survival. The FDA granted RMAT designati

Tone
Positive 74/100
Event
Earnings
Published
08 Jul 2026 11:11
Source
Quartr
Benzinga España Direct company coverage

TScan Therapeutics (TCRX) Stock Analysis Report | Financials & Insights

This report provides a detailed financial analysis of TScan Therapeutics (TCRX), a clinical-stage biotechnology company focused on developing TCR-T therapies for cancer. It covers general company information, stock performance metrics, Benzinga Edge rankings, financial health ind

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:09
Source
Benzinga España
TradingView Direct company coverage

Enterprise value to EBITDA forward of TScan Therapeutics, Inc. – NASDAQ:TCRX

This article examines the enterprise value to EBITDA forward for TScan Therapeutics, Inc. (NASDAQ: TCRX). It primarily presents a snapshot of financial data and company information available on TradingView, covering market specifics and financial metrics. The focus is on the valu

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 11:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of TScan Therapeutics, Inc. – NASDAQ:TCRX

This article provides financial information for TScan Therapeutics, Inc. (NASDAQ: TCRX), focusing on its enterprise value to EBIT forward. It indicates a period value and details regarding changes in this metric, accessible through TradingView's platform.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:10
Source
TradingView
Investing.com Direct company coverage

TScan Therapeutics at H.C. Wainwright: phase iii push gains pace

TScan Therapeutics presented at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, announcing the transition of its lead program, TSC-101, into a phase III study. The company highlighted encouraging phase I data showing 100% relapse-free survival in a treated subset

Tone
Positive 80/100
Event
Market update
Published
30 Jun 2026 18:39
Source
Investing.com
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS)

The article highlights positive analyst sentiments in the Healthcare sector for Definium Therapeutics (DFTX), TScan Therapeutics (TCRX), and PACS Group Inc (PACS). Analysts from JonesTrading, Wedbush, and J.P. Morgan reiterated Buy ratings for the respective companies, citing sig

Tone
Positive 75/100
Event
Analyst action
Published
28 Jun 2026 10:11
Source
The Globe and Mail
TradingView Direct company coverage

Enterprise value to revenue forward of TScan Therapeutics, Inc. – NASDAQ:TCRX

The article discusses the enterprise value to revenue forward for TScan Therapeutics, Inc. (NASDAQ: TCRX). It appears to be a financial data snippet from TradingView, indicating no specific value or change but rather the financial metric is available. The content primarily shows

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 14:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of TScan Therapeutics, Inc. – BOATS:TCRX

This article provides the "Price to sales forward" financial metric for TScan Therapeutics, Inc. (TCRX) on the Blue Ocean Alternative Trade System (BOATS). It is presented within the context of TradingView's financial data offerings for investors.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 12:10
Source
TradingView
Stock Titan Direct company coverage

TScan Therapeutics to speak at H.C. Wainwright cell therapy event June 30

TScan Therapeutics (Nasdaq:TCRX), a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company will host a fireside chat at 11:30 a.m. ET, with a live webcast and 90-day replay

Tone
Positive 61/100
Event
Market update
Published
24 Jun 2026 11:14
Source
Stock Titan
GlobeNewswire Direct company coverage

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

TScan Therapeutics, a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company will host a fireside chat on June 30, 2026, at 11:30 a.m. ET, discussing its T cell receptor (TCR)-engineered T c

Tone
Positive 61/100
Event
Market update
Published
24 Jun 2026 11:14
Source
GlobeNewswire
TradingView Direct company coverage

TCRX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for TScan Therapeutics, Inc. (TCRX) stock, outlining current price, historical performance, and analyst opinions for future price movements. It also includes key financial metrics such as EPS, revenue, market capitalization, and u

Tone
Positive 60/100
Event
Earnings
Published
24 Jun 2026 09:11
Source
TradingView
GuruFocus Direct company coverage

TCRX Reiterated by Needham -- Price Target Maintained at $6.00

Needham analyst Gil Blum reiterated a "Buy" rating for TScan Therapeutics (TCRX) and maintained a price target of $6.00. The stock is considered undervalued by 48.2% based on GuruFocus's GF Value™ of $1.68 compared to its current price of $0.87. Despite an average GF Score™ of 50

Tone
Positive 71/100
Event
Analyst action
Published
23 Jun 2026 17:10
Source
GuruFocus
GuruFocus Direct company coverage

TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00

Wedbush has reiterated an Outperform rating for TScan Therapeutics (TCRX), maintaining a price target of $5.00. Despite a current market price of $0.87, GuruFocus estimates the stock to be 48.2% undervalued with a GF Value™ of $1.68. While analysts express confidence in the compa

Tone
Positive 67/100
Event
Analyst action
Published
23 Jun 2026 17:10
Source
GuruFocus
Sahm Direct company coverage

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The study showed 11 of 14 patients achieved complete donor chimerism short

Tone
Positive 71/100
Event
Market update
Published
23 Jun 2026 16:39
Source
Sahm
Stock Titan Direct company coverage

TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial

TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101, a TCR-T cell therapy for blood cancer patients post-allogeneic stem cell transplant. The data show 11 of 14 patients achieved complete donor chimerism, with 93% exhibiting d

Tone
Positive 82/100
Event
Market update
Published
23 Jun 2026 03:39
Source
Stock Titan
grafa.com Direct company coverage

TScan reports Phase 1 data for TSC-101 blood cancer trial

TScan Therapeutics announced promising initial Phase 1 data for its TSC-101 treatment in blood cancer patients, with 11 out of 14 achieving complete donor chimerism. The company's shares traded down following the news, and TScan expects to enroll the first patient in its pivotal

Tone
Negative 38/100
Event
Guidance
Published
22 Jun 2026 13:35
Source
grafa.com
Investing.com Nigeria Direct company coverage

TScan reports trial data for blood cancer treatment TSC-101 By Investing.com

TScan Therapeutics Inc. (NASDAQ:TCRX) released promising data from Cohort C of its ALLOHA Phase 1 study for TSC-101, a blood cancer treatment. The study showed 11 out of 14 treated patients achieved complete donor chimerism, and the infusions were generally well-tolerated. Despit

Tone
Positive 66/100
Event
Market update
Published
22 Jun 2026 11:40
Source
Investing.com Nigeria
Investing.com Canada Direct company coverage

Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com

This article announces that Tscan Therapeutics Inc. filed a Form 8K on June 22nd. The brief post from Investing.com includes general market data and related news but offers no specifics about the content of the Form 8K filing itself. The article also touches on various market ind

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 11:40
Source
Investing.com Canada
Stock Titan Direct company coverage

TScan says 11 of 14 patients hit complete donor chimerism after TSC-101

TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101, reporting that 11 out of 14 patients achieved complete donor chimerism within approximately three weeks of their first infusion. The company also confirmed a ~90% manufacturi

Tone
Positive 81/100
Event
Market update
Published
22 Jun 2026 10:40
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX

This article provides information about the number of shareholders of TScan Therapeutics, Inc. (NASDAQ: TCRX) through a TradingView interface. It presents data points for "Period," "Value," "Change," and "Change %" without specifying the actual shareholder numbers or the periods

Tone
Neutral 50/100
Event
Market update
Published
20 Jun 2026 05:40
Source
TradingView
TradingKey Direct company coverage

TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for TScan Therapeutics Inc (TCRX), focusing on its business segments, regional revenue, and profit contribution. It notes that relevant financial data for FY2025 has not yet been disclosed by the company. The only specific financial detai

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:39
Source
TradingKey